

Input:

Study title:

Felbamate add-on therapy for drug-resistant focal epilepsy

1. **Abstract title:** Felbamate: a double-blind controlled trial in patients undergoing presurgical evaluation of partial seizures.

This double-blind, placebo-controlled trial studied the efficacy and safety of felbamate as an investigational antiepileptic drug. [...] This trial demonstrated that felbamate is an effective and safe treatment for refractory partial-onset seizures.

2. **Abstract title:** Felbamate for partial seizures: results of a controlled clinical trial.

In a double-blind, placebo-controlled trial, 56 patients with partial seizures and a requirement for four or more seizures per month despite concomitant therapeutic blood levels of phenytoin and carbamazepine were given Felbamate. [...] Overall, this trial suggests that Felbamate is a safe and effective treatment for severely refractory epilepsy.

3. **Abstract title:** Felbamate: a clinical trial for complex partial seizures.

This randomized, double-blind, three-period crossover study found that felbamate (FBM) was well-tolerated by 28 patients with complex partial [...] Although there was no significant reduction in seizure frequency between placebo and FBM periods, the data suggested a strong antiseizure effect of FBM when the lower CBZ levels were taken into account.

Generated Technical Summary:

The evidence suggests that Felbamate is an effective and safe add-on therapy for patients with drug-resistant focal epilepsy. The trial showed that Felbamate was superior to placebo in reducing seizures, with no major adverse events reported. Additionally, the data suggests that Felbamate may have an antiseizure effect when combined with lower levels of carbamazepine.

Target:

In view of the methodological deficiencies, the limited number of included studies and the differences in outcome measures, we have found no reliable evidence to support the use of felbamate as an add-on therapy in people with drug-resistant focal-onset epilepsy. A large-scale, randomised controlled trial conducted over a longer period of time is required to inform clinical practice.